Herbert Skip Virgin

2020

In 2020, Herbert Skip Virgin earned a total compensation of $1.1M as Executive Vice President, Research and Chief Scientific Officer at Vir Biotechnology, a 44% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$374,311
Salary$636,525
Other$95,400
Total$1,106,236

Virgin received $636.5K in salary, accounting for 58% of the total pay in 2020.

Virgin also received $374.3K in non-equity incentive plan and $95.4K in other compensation.

Rankings

In 2020, Herbert Skip Virgin's compensation ranked 8,205th out of 13,090 executives tracked by ExecPay. In other words, Virgin earned more than 37.3% of executives.

ClassificationRankingPercentile
All
8,205
out of 13,090
37th
Division
Manufacturing
3,480
out of 5,621
38th
Major group
Chemicals And Allied Products
1,403
out of 2,254
38th
Industry group
Drugs
1,221
out of 1,954
38th
Industry
Biological Products, Except Diagnostic Substances
287
out of 411
30th
Source: SEC filing on April 6, 2021.

Virgin's colleagues

We found four more compensation records of executives who worked with Herbert Skip Virgin at Vir Biotechnology in 2020.

2020

Steven Rice

Vir Biotechnology

Chief Administrative Officer

2020

Howard Horn

Vir Biotechnology

Chief Financial Officer

2020

George Scangos

Vir Biotechnology

Chief Executive Officer

2020

Michael Kamarck

Vir Biotechnology

Chief Technology Officer

News

You may also like